Loading clinical trials...
Loading clinical trials...
A Phase I, Open Label, Parallel Group Trial To Evaluate Safety And Immunogenicity Of Three Nasal Immunisations Using A Fixed Dose-Level Of HIV gp140 V2 Loop Deleted Protein Adjuvanted With LTK63 Followed By Intramuscular Boosting With HIV gp140 V2 Loop Deleted Protein Adjuvanted With MF59 When Administered To Healthy Adults
Conditions
Interventions
Human Immunodeficiency Virus glycoprotein 140 (vaccine)
HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant
+1 more
Locations
1
United Kingdom
St George's Vaccine Institute
London, England, United Kingdom
Start Date
September 1, 2006
Primary Completion Date
November 1, 2007
Completion Date
March 1, 2008
Last Updated
April 15, 2008
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
St George's, University of London
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions